Compare Koninklijke Philips NV (PHG) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs 22nd Century Group Inc — how do they compare? Koninklijke Philips NV trades at $24.94 (market cap $24.61B), while 22nd Century Group Inc trades at $2.17 (market cap $1.50M). The key difference: Koninklijke Philips NV is far larger — about 16406.7× 22nd Century Group Inc's market cap, and Koninklijke Philips NV pays a 4.05% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| PHG | XXII | |
|---|---|---|
Market Cap | $24.61B | $1.50M |
Sector | Health | Technology |
52-Week High | $32.91 | $594.00 |
52-Week Low | $25.02 | $2.13 |
Enterprise Value | $31.21B | -$2.81M |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $25.29, down 2.32% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $0.57 beating expectations of $0.40, and positive net income of $895M in 2025 reversing previous losses. Recent product launches in women's health and AI-powered medical devices demonstrate innovation momentum.
The outlook is mixed with strong fundamentals and analyst support (36% buy ratings) offset by technical weakness. Key opportunities include margin expansion and new product adoption, while risks involve cybersecurity threats and competitive pressures in healthcare technology.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
